GlassScriptPhysician profile
Bo Tang
NPI 1710449517
$2,714.28
in general payments reported to CMS, 2019-2025
18 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $237 · 2023: $186 · 2024: $1,235 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $766.58 | 2023-2025 | Tezspire, Fasenra, Andexxa |
| Glaxosmithkline, LLC. | $363.05 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $349.99 | 2022-2025 | Dupixent |
| Pulmonx Corporation | $261.96 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $151.79 | 2024 | |
| Abiomed | $127.34 | 2024 | Impella |
| Shionogi INC | $118.60 | 2025 | Fetroja |
| Amgen INC. | $115.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.87 | 2024-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $67.77 | 2024-2025 | Glassia |
| Viatris Specialty LLC | $55.06 | 2025 | Yupelri |
| Acadia Pharmaceuticals INC | $49.72 | 2025 | Nuplazid |
| Mindray Ds USA, INC. | $44.81 | 2024 | Te7 Max, Te X |
| Pfizer INC. | $36.00 | 2023-2024 | |
| Inspire Medical Systems, INC. | $33.55 | 2025 | Inspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.85 | 2024 | Dificid, Prevymis, Zerbaxa |
| Grifols USA, LLC | $19.04 | 2025 | Prolastin-C Liquid |
| Adc Therapeutics America, INC. | $16.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.